Health & Fitness
Health and Fitness
Health and Fitness
Tue, May 11, 2010 Rosetta Genomics to Present at the 6th Annual Rodman and Renshaw Global Healthcare Conference
REHOVOT, Israel & PHILADELPHIA--([ BUSINESS WIRE ])--Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the Company will be presenting at the 6th Annual Rodman & Renshaw Global Healthcare Conference being held at the Grosvenor House Hotel in London, England from May 16th a" 18th, 2010. Kenneth A. Berlin., President and CEO of Rosetta Genomics, will deliver the Companya™s corporate presentation on Monday, May 17th, at 2:50 PM Greenwich Mean Time (9:50 AM Eastern Daylight Time.)
Company management will be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Healthcare Conference. For those who would like to schedule an appointment with Rosetta Genomicsa™ management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at [ afields@lhai.com ] or contact your Rodman & Renshaw representative.
The presentation will be webcast live at [ http://www.wsw.com/webcast/rrshq17/rosg ]and at the Investor Relations section of the Companya™s website at [ www.rosetta.com ] where it will also be archived for 90 days.
About microRNAs
MicroRNAs (miRNAs) are recently discovered, small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. The unique advantage of microRNAs as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks. It has been suggested that their small size (19 to 21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced. To learn more about microRNAs, please visit [ www.rosettagenomics.com ] .
About miRviewa" Products
miRviewa" products are a series of microRNA-based diagnostic tests developed by Rosetta Genomics. miRviewa" mets accurately identifies the primary tumor site in metastatic cancer and Cancer of Unknown Primary (CUP) patients. miRviewa" squamous accurately identifies the squamous subtype of NSCLC, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain targeted therapies. miRviewa" meso diagnoses mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung and pleura. This test can be used to rule out mesothelioma in patients diagnosed with a tumor in the lung or pleura, who may have been exposed to asbestos in the past. miRviewa" tests are designed to provide objective diagnostic data; it is the treating physiciana™s responsibility to diagnose and administer the appropriate treatment. The companya™s tests are now being offered through distributors around the globe. For more information, please visit [ www.mirviewdx.com ] .
About Rosetta Genomics
Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the companya™s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The companya™s first three microRNA-based tests, miRviewa" squamous, miRviewa" mets and miRviewa" meso, are commercially available through its Philadelphia-based CAP accredited, CLIA-certified lab. Rosetta Genomics is the 2008 winner of the Wall Street Journala™s Technology Innovation Awards in the medical/biotech category. To learn more, please visit [ www.rosettagenomics.com ] .
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosettaa™s future expectations, plans and prospects, including without limitation, statements relating to Rosettaa™s intellectual property portfolio, and its potential to provide protection to Rosettaa™s research and development efforts, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosettaa™s approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which may never lead to commercially accepted products or services; Rosettaa™s ability to obtain, maintain and protect its intellectual property; Rosettaa™s ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosettaa™s need and ability to obtain additional funding to support its business activities; Rosettaa™s dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosettaa™s ability to successfully develop its products and services; Rosettaa™s ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosettaa™s technology; competition from others using technology similar to Rosettaa™s and others developing products for similar uses; Rosettaa™s dependence on collaborators; and Rosettaa™s short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosettaa™s Annual Report on Form 20-F for the year ended December 31, 2009 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosettaa™s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
